Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2015

01-12-2015 | Original Article

Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells

Authors: Lijun Wang, Ying Wang, Huaqing Du, Yao Jiang, Zhichao Tang, Hongyi Liu, Hua Xiang, Hong Xiao

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2015

Login to get access

Abstract

Purposes

ER520, a derivative of indenoisoquinoline, is a patented compound. This study was designed to screen its biological properties and to evaluate its antineoplastic and antiangiogenic effect.

Methods

Western blot was employed to monitor the ERα and ERβ protein expression in human breast cancer MCF-7 cells and endometrial carcinoma Ishikawa cells. MTT assay was employed to determine cell proliferation. Cell adhesion, scratch and Transwell assay were utilized to estimate the ability of cellular adhesion, migration and invasion. ELISA kit was applied to detect the VEGF products in culture medium. In addition, the inhibitory effect of ER520 on the vessel-like construction of HUVEC cells and the angiogenesis of chicken embryos was investigated. The efficiency of ER520 on tumor growth in nude mice was also assessed.

Results

ER520 inhibited the expression of ERα in MCF-7 and Ishikawa cells, while it increased ERβ protein level. ER520 also suppressed the proliferation of MCF-7 and Ishikawa cells. Due to its remarkably negative role in cell adhesion, migration and invasion, ER520 showed a potential ability of inhibiting tumor metastasis. Meanwhile, ER520 reduced the VEGF secretion of MCF-7 and Ishikawa cells, prevented the formation of VEGF-stimulated tubular structure and the cell migration of HUVEC cells, and inhibited the angiogenesis of chicken chorioallantoic membrane. Animal experiment also demonstrated that ER520 could frustrate the in vivo tumor growth and the inhibitory ratio was 48.5 % compared with control group.

Conclusion

Our findings indicate that ER520 possesses the competence to be a candidate against breast cancer and angiogenesis.
Literature
1.
Masuda S (2012) Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy. Pathol Int 62:295–302CrossRefPubMed
2.
Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134–139CrossRefPubMed
3.
Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150–1154CrossRefPubMed
4.
Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53CrossRefPubMed
5.
Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81:1535–1565PubMed
6.
Menasce LP, White GR, Harrison CJ, Boyle JM (1993) Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 17:263–265CrossRefPubMed
7.
Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA (1997) Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258–4265PubMed
8.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 277:1508–1510CrossRefPubMed
9.
Quaynor SD, Stradtman EW Jr, Kim HG, Shen Y, Chorich LP, Schreihofer DA, Layman LC (2013) Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant. N Engl J Med 369:164–171CrossRefPubMed
10.
Morris E, Currie H (2013) Estrogen deficiency: education for all. Menopause Int 19:55PubMed
11.
12.
Janner M, Flück CE, Mullis PE (2012) Impact of estrogen replacement throughout childhood on growth, pituitary-gonadal axis and bone in a 46, XX patient with CYP19A1 deficiency. Horm Res Paediatr 78:261–268CrossRefPubMed
13.
Karimian E, Sävendahl L (2011) Estrogen signaling in growth plate cartilage. Endocr Dev 21:42–51CrossRefPubMed
14.
Younes M, Honma N (2011) Estrogen receptor β. Arch Pathol Lab Med 135:63–66PubMed
15.
Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55:371–374PubMedCentralCrossRefPubMed
16.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRef
17.
18.
19.
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL (2012) Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res 18:118–126PubMedCentralCrossRefPubMed
20.
21.
22.
Nath A, Sitruk-Ware R (2009) Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric 12:188–205CrossRefPubMed
23.
Birkhäuser M (2012) Selective estrogen receptor modulators for prevention and treatment of postmenopausal osteoporosis. Ther Umsch 69:163–172CrossRefPubMed
24.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRef
25.
Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659–2669PubMed
26.
Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastia CR, Salama SA (2011) The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 126:78–86PubMedCentralCrossRefPubMed
27.
González Martín A, de la Cruz S, Márquez R (2010) Adjuvant endocrine therapy in premenopausal women with breast cancer. Breast Cancer Res Treat 123:43–47
28.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189–2197CrossRefPubMed
29.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL III, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295:2727–2741CrossRefPubMed
30.
Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 65:550–563CrossRefPubMed
31.
Esser S, Lampugnani MG, Corada M, Dejana E, Risau W (1998) Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 110:2065–2077
32.
Kevil CG, Payne DK, Mire E, Alexander JS (1998) Vascular permeability factor/vascular endothelial growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273:15099–15103CrossRefPubMed
33.
Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB (2003) VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 17:752–754PubMed
34.
Yoshiji H, Harris SR, Thorgeirsson UP (1997) Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57:3924–3928PubMed
35.
Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M (2003) Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162:1913–1926PubMedCentralCrossRefPubMed
36.
Desai S, Laskar S, Pandey BN (2013) Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal 25:1780–1791CrossRefPubMed
37.
Ahluwalia A, Jones MK, Szabo S, Tarnawski AS (2013) Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism, Biochem Biophys Res Commun 437:515–520PubMed
38.
De Jong JS, van Diest PJ, van der Valk P, Baak JP (1998) Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 184:44–52
39.
Chinese Pat., 101 693 688 A, 2010. International Pat., 047515, 2011. US Pat., 0085140A1, 2013
40.
Murdoch AD, Grady LM, Ablett MP, Katopodi T, Meadows RS, Hardingham TE (2007) Chondrogenic differentiation of human bone marrow stem cells in transwell cultures: generation of scaffold-free cartilage. Stem Cells 25:2786–2796CrossRefPubMed
41.
Arnaoutova I, George J, Kleinman HK, Benton G (2009) The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12:267–274CrossRefPubMed
42.
Yang EY, Moses HL (1990) Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111:731–741CrossRefPubMed
43.
Brünner N, Bronzert D, Vindeløv LL, Rygaard K, Spang-Thomsen M, Lippman ME (1989) Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49:1515–1520PubMed
44.
Mendoza RA, Enriquez MI, Mejia SM, Moody EE, Thordarson G (2011) Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol 208:1–9PubMedCentralCrossRefPubMed
45.
Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ (2008) Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109:241–250CrossRefPubMed
46.
Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D (2013) The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 44:1047–1054CrossRefPubMed
47.
Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2000) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 464:423–428
48.
Haldosén LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382:665–672CrossRefPubMed
49.
50.
Shen J (2012) Rethink the war on cancer—directional metastasis driven by survival advantage gradient. Med Hypotheses 79:896CrossRefPubMed
51.
Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, Nogi H, Kawase K, Takeyama H, Toriumi Y, Uchida K, Kobayashi M, Kanehira C, Suzuki M, Ando N, Natori K, Kuraishi Y (2012) Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 19:218–237CrossRefPubMed
52.
53.
Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617:437–444CrossRefPubMed
54.
Kok M, Linn SC (2010) Gene expression profiles of the oestrogen receptor in breast cancer. Neth J Med 68:291–302PubMed
55.
Perrot-Applanat M, Di Benedetto M (2012) Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr 6:547–553PubMedCentralCrossRefPubMed
56.
Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237–239CrossRefPubMed
57.
Pribluda VS, Gubish ER, Lavallee TM, Treston A, Swartz GM, Green SJ (2000) 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19:173–179CrossRefPubMed
Metadata
Title
Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells
Authors
Lijun Wang
Ying Wang
Huaqing Du
Yao Jiang
Zhichao Tang
Hongyi Liu
Hua Xiang
Hong Xiao
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2838-0

Other articles of this Issue 6/2015

Cancer Chemotherapy and Pharmacology 6/2015 Go to the issue

Original Article

Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy

Original Article

Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer

Original Article

Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression

Original Article

Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts

Original Article

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer

Clinical Trial Report

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits